Fibroblast Growth Factor 23 and Adverse Clinical Outcomes in Type 2 Diabetes: a Bitter-Sweet SymphonyYeung, S. M. H., Bakker, S. J. L., Laverman, G. D. & De Borst, M. H., 28-Aug-2020, In : Current diabetes reports. 20, 10, 9 p., 50.
Research output: Contribution to journal › Review article › Academic › peer-review
Purpose of Review: Fibroblast growth factor 23 (FGF23) is a key phosphate-regulating hormone that has been associated with adverse outcomes in patients with chronic kidney disease (CKD). Emerging data suggest that FGF23 plays a specific role in type 2 diabetes, partly independent of kidney function. We aimed to summarize current literature on the associations between FGF23 and outcomes in patients with type 2 diabetes with or without CKD. Recent Findings: Several cohort studies have shown strong associations between plasma FGF23 and cardiovascular outcomes in diabetic CKD. Moreover, recent data suggest that FGF23 are elevated and may also be a risk factor for cardiovascular disease and mortality in type 2 diabetes patients without CKD, although the magnitude of the association is smaller than in CKD patients. Summary: Diabetes-related factors may influence plasma FGF23 levels, and a higher FGF23 levels seem to contribute to a higher cardiovascular and mortality risk in patients with type 2 diabetes. Although this risk may be relevant in diabetic individuals with preserved kidney function, it is strongly accentuated in diabetic nephropathy. Future studies should clarify if FGF23 is merely a disease severity marker or a contributor to adverse outcomes in type 2 diabetes and establish if antidiabetic medication can modify FGF23 levels.
|Number of pages||9|
|Journal||Current diabetes reports|
|Publication status||Published - 28-Aug-2020|
- Mineral metabolism, Diabetes, Kidney disease, Cardiovascular disease, CHRONIC KIDNEY-DISEASE, ANGIOTENSIN-ALDOSTERONE SYSTEM, VITAMIN-D, FGF23 LEVELS, MINERAL METABOLISM, OBESE ADOLESCENTS, AFRICAN-AMERICANS, PHOSPHATE BINDERS, PLASMA-LEVELS, MORTALITY